bioMérieux - First-Half 2014 Results

Solid growth in first-half sales

• Up 7.9%, including BioFire and at constant exchange rates
• Up 4.2% at constant exchange rates and scope of consolidation

2014 financial objectives maintained

Contributive operating income before non-recurring items* of €94 million, reflecting a material negative currency effect and major investments in production, sales & marketing, and innovation

Noteworthy advances in molecular biology with the integration of BioFire

CE marking for VIRTUOTM, the new generation blood culture system

“bioMérieux reported solid growth in net sales in the first half of 2014,” said Chief Executive Officer Alexandre Mérieux, “totaling 7.9% at constant exchange rates. With the notable exception of the Asia-Pacific region, our business enjoyed satisfactory growth in all geographies. However, as we anticipated, the Group’s results were affected by the major decline in most of our functional currencies against the euro and by significant production expenditure at our Durham plant. In this difficult environment, we implemented an operating cost control plan. Thanks to our sales momentum and greater financial discipline, we are maintaining our objectives for the full year.”

Marcy l'Etoile, France - September 3, 2014 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 2 under the chairmanship of Jean-Luc Belingard to approve the consolidated financial statements for the six months ended June 30, 2014. The Statutory Auditors had performed a limited review of the financial statements.

* Contributive operating income before non-recurring items corresponds to operating income before non-recurring items, before non-recurring BioFire acquisition and integration costs and before accounting entries relating to BioFire purchase price allocation (see Appendix 2). Operating income before non-recurring items corresponds to operating income before “material, extraordinary and non-recurring items”, which are included in “other non-recurring operating income and expenses.”